114 related articles for article (PubMed ID: 27111337)
1. Interplay between PREX2 mutations and the PI3K pathway and its effect on epigenetic regulation of gene expression in NRAS-mutant melanoma.
Lissanu Deribe Y
Small GTPases; 2016 Jul; 7(3):178-85. PubMed ID: 27111337
[TBL] [Abstract][Full Text] [Related]
2. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.
Lissanu Deribe Y; Shi Y; Rai K; Nezi L; Amin SB; Wu CC; Akdemir KC; Mahdavi M; Peng Q; Chang QE; Hornigold K; Arold ST; Welch HC; Garraway LA; Chin L
Proc Natl Acad Sci U S A; 2016 Mar; 113(9):E1296-305. PubMed ID: 26884185
[TBL] [Abstract][Full Text] [Related]
3. Methylation and mutation of the inhibin‑α gene in human melanoma cells and regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent.
Ko H; Ahn HJ; Kim YI
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958114
[TBL] [Abstract][Full Text] [Related]
4. Replication Study: Melanoma genome sequencing reveals frequent
Horrigan SK; Courville P; Sampey D; Zhou F; Cai S;
Elife; 2017 Jan; 6():. PubMed ID: 28100394
[TBL] [Abstract][Full Text] [Related]
5. PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.
Mense SM; Barrows D; Hodakoski C; Steinbach N; Schoenfeld D; Su W; Hopkins BD; Su T; Fine B; Hibshoosh H; Parsons R
Sci Signal; 2015 Mar; 8(370):ra32. PubMed ID: 25829446
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic insights into the role of truncating PREX2 mutations in melanoma.
Lissanu Deribe Y
Mol Cell Oncol; 2016 May; 3(3):e1160174. PubMed ID: 27314100
[TBL] [Abstract][Full Text] [Related]
7. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
Emran AA; Chinna Chowdary BR; Ahmed F; Hammerlindl H; Huefner A; Haass NK; Schuehly W; Schaider H
Cancer Med; 2019 Mar; 8(3):1186-1196. PubMed ID: 30793515
[TBL] [Abstract][Full Text] [Related]
8. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction.
Yeung YT; Fan S; Lu B; Yin S; Yang S; Nie W; Wang M; Zhou L; Li T; Li X; Bode AM; Dong Z
Carcinogenesis; 2020 May; 41(3):377-389. PubMed ID: 31241130
[TBL] [Abstract][Full Text] [Related]
9. ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.
Ryan MB; Finn AJ; Pedone KH; Thomas NE; Der CJ; Cox AD
Mol Cancer Res; 2016 Oct; 14(10):1009-1018. PubMed ID: 27418645
[TBL] [Abstract][Full Text] [Related]
10. RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.
Laugier F; Finet-Benyair A; André J; Rachakonda PS; Kumar R; Bensussan A; Dumaz N
Oncotarget; 2015 Sep; 6(29):28120-31. PubMed ID: 26356562
[TBL] [Abstract][Full Text] [Related]
11. p21-activated Kinases (PAKs) Mediate the Phosphorylation of PREX2 Protein to Initiate Feedback Inhibition of Rac1 GTPase.
Barrows D; Schoenfeld SM; Hodakoski C; Silkov A; Honig B; Couvillon A; Shymanets A; Nürnberg B; Asara JM; Parsons R
J Biol Chem; 2015 Nov; 290(48):28915-31. PubMed ID: 26438819
[TBL] [Abstract][Full Text] [Related]
12. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
13. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
14. A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity.
Conde-Perez A; Gros G; Longvert C; Pedersen M; Petit V; Aktary Z; Viros A; Gesbert F; Delmas V; Rambow F; Bastian BC; Campbell AD; Colombo S; Puig I; Bellacosa A; Sansom O; Marais R; Van Kempen LC; Larue L
Nat Commun; 2015 Aug; 6():8093. PubMed ID: 26307673
[TBL] [Abstract][Full Text] [Related]
15. Melanoma genome sequencing reveals frequent PREX2 mutations.
Berger MF; Hodis E; Heffernan TP; Deribe YL; Lawrence MS; Protopopov A; Ivanova E; Watson IR; Nickerson E; Ghosh P; Zhang H; Zeid R; Ren X; Cibulskis K; Sivachenko AY; Wagle N; Sucker A; Sougnez C; Onofrio R; Ambrogio L; Auclair D; Fennell T; Carter SL; Drier Y; Stojanov P; Singer MA; Voet D; Jing R; Saksena G; Barretina J; Ramos AH; Pugh TJ; Stransky N; Parkin M; Winckler W; Mahan S; Ardlie K; Baldwin J; Wargo J; Schadendorf D; Meyerson M; Gabriel SB; Golub TR; Wagner SN; Lander ES; Getz G; Chin L; Garraway LA
Nature; 2012 May; 485(7399):502-6. PubMed ID: 22622578
[TBL] [Abstract][Full Text] [Related]
16. Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment.
Coleman DJ; Chagani S; Hyter S; Sherman AM; Löhr CV; Liang X; Ganguli-Indra G; Indra AK
Mol Cancer Res; 2015 Jan; 13(1):186-96. PubMed ID: 25189354
[TBL] [Abstract][Full Text] [Related]
17. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
18. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
[TBL] [Abstract][Full Text] [Related]
19.
Lu XX; Cao LY; Chen X; Xiao J; Zou Y; Chen Q
Biomed Res Int; 2016; 2016():2476842. PubMed ID: 27822469
[No Abstract] [Full Text] [Related]
20. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
